Preventing staphylococcus aureus sepsis through the inhibition of its agglutination in blood

PLoS Pathogens

Volumn 7, Issue 10, 2011, Pages

  McAdow, Molly ^a   Kim, Hwan Keun ^a   DeDent, Andrea C ^a   Hendrickx, Antoni P A ^a   Schneewind, Olaf ^a   Missiakas, Dominique M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADSA PROTEIN; BACTERIAL PROTEIN; CLFA PROTEIN; CLFB PROTEIN; COA PROTEIN; COAGULASE; DABIGATRAN ETEXILATE; FIBRIN; FIBRINOGEN; FNBPA PROTEIN; FNBPB PROTEIN; ISDA PROTEIN; ISDB PROTEIN; ISDC PROTEIN; ISDH PROTEIN; PROTHROMBIN; SASA PROTEIN; SASB PROTEIN; SASC PROTEIN; SASD PROTEIN; SASF PROTEIN; SASG PROTEIN; SDRC PROTEIN; SDRD PROTEIN; SDRE PROTEIN; SRTA PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; VWB PROTEIN; VWBP PROTEIN; ANTITHROMBIN; CARRIER PROTEIN; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULATING AGENT; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME RELEASE; HEART MUSCLE; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION; MOUSE; NONHUMAN; SEPSIS; STAPHYLOCOCCUS AUREUS; THROMBOEMBOLISM; VIRUS GENE; ANIMAL; ANTIGEN ANTIBODY REACTION; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG EFFECT; HEART; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; LONGEVITY; METABOLISM; MICROBIOLOGY; PASSIVE IMMUNIZATION; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; STAPHYLOCOCCUS INFECTION; ULTRASTRUCTURE;

ANIMALIA; BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

AGGLUTINATION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTITHROMBINS; BACTERIAL PROTEINS; CARRIER PROTEINS; COAGULANTS; COAGULASE; DISEASE MODELS, ANIMAL; HEART; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNIZATION, PASSIVE; LONGEVITY; MICE; MICE, INBRED BALB C; MYOCARDIUM; PROTEIN BINDING; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VON WILLEBRAND FACTOR;

EID: 80055076614     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002307     Document Type: Article

References (67)

1. Lowy FD, (1998) Staphylococcus aureus infections. New Engl J Med 339: 520-532.
2. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
3. DeLeo FR, Chambers HF, (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: 629-641.
4. Fowler VGJ, Miro JM, Hoen B, Cabell CH, Abrutyn E, et al. (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
5. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF, (2010) Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375: 1557-1568.
6. Foster TJ, (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3: 948-958.
7. Walsh EJ, Miajlovic H, Gorkun OV, Foster TJ, (2008) Identification of the Staphylococcus aureus MSCRAMM clumping factor B (ClfB) binding site in the alphaC-domain of human fibrinogen. Microbiology 154: 550-558.
8. Cheng AG, DeDent AC, Schneewind O, Missiakas DM, (2011) A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol 19: 225-232.
9. Doolittle RF, (2003) Structural basis of the fibrinogen-fibrin transformation: contributions from X-ray crystallography. Blood Rev 17: 33-41.
10. Panizzi P, Friedrich R, Fuentes-Prior P, Richter K, Bock PE, et al. (2006) Fibrinogen substrate recognition by staphylocoagulase (pro)thrombin complexes. J Biol Chem 281: 1179-1187.
11. Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, et al. (2003) Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425: 535-539.
12. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, et al. (2010) Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6: e1001036.
13. Loeb L, (1903) The influence of certain bacteria on the coagulation of blood. J Med Res 10: 407.
14. Kolle W, Otto R, (1902) Die Differenzierung der Staphylokokken mittelst der Agglutination. Z Hygiene 41: 369-379.
15. McDevitt D, Francois P, Vaudaux P, Foster TJ, (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11: 237-248.
16. Hawiger J, Timmons S, Strong DD, Cottrell BA, Riley M, et al. (1982) Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. Biochemistry 21: 1407-1413.
17. McDevitt D, Francois P, Vaudaux P, Foster TJ, (1995) Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol Microbiol 16: 895-907.
18. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, et al. (1997) Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 247: 416-424.
19. Strong DD, Laudano AP, Hawiger J, Doolittle RF, (1982) Isolation, characterization and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle. Biochemistry 21: 1414-1420.
20. Ganesh VK, Rivera JJ, Smeds E, Ko Y-P, Bowden MG, et al. (2008) A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog 4: e1000226.
21. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster TJ, (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580.
22. Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, et al. (1995) Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63: 4738-4743.
23. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, et al. (2010) Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78: 1717-1727.
24. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, et al. (2003) Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71: 6864-6870.
25. Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, et al. (2006) Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of Tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 2751-2755.
26. Birch-Hirschfeld L, (1934) Über die Agglutination von Staphylokokken durch Bestandteile des Säugetierblutplasmas. Klinische Woschenschrift 13: 331.
27. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, et al. (2010) IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28: 6382-6392.
28. Mazmanian SK, Liu G, Ton-That H, Schneewind O, (1999) Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285: 760-763.
29. Bae T, Banger AK, Wallace A, Glass EM, Aslund F, et al. (2004) Staphylococcus aureus virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc Natl Acad Sci U S A 101: 12312-12317.
30. Kaida S, Miyata T, Yoshizawa Y, Kawabata S, Morita T, et al. (1987) Nucleotide sequence of the staphylocoagulase gene: its unique COOH-terminal 8 tandem repeats. J Biochem 102: 1177-1186.
31. Bjerketorp J, Nilsson M, Ljungh A, Flock JI, Jacobsson K, et al. (2002) A novel von Willebrand factor binding protein expressed by Staphylococcus aureus. Microbiology 148: 2037-2044.
32. Palma M, Nozohoor S, Schennings T, Heimdahl A, Flock JI, (1996) Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect Immun 64: 5284-5289.
33. Palma M, Wade D, Flock M, Flock JI, (1998) Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen. J Biol Chem 273: 13177-13181.
34. Ní Eidhin D, Perkins S, Francois P, Vaudaux P, Höök M, et al. (1998) Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol 30: 245-257.
35. Hawiger J, Hammond DK, Timmons S, (1975) Human fibrinogen possesses binding sites for staphylococci on Aalpha and Bbeta polypeptide chains. Nature 258: 643-645.
36. Stranger-Jones YK, Bae T, Schneewind O, (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Nat Acad Sci U S A 103: 16942-16947.
37. Hijikata-Okunomiya A, Kataoka N, (2003) Argatroban inhibits staphylothrombin. J Thromb Haemost 1: 2060-2061.
38. Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P, (2010) Dabigatran inhibits Staphylococcus aureus coagulase activity. J Clin Microbiol 48: 4248-4250.
39. Haul NH, Nar H, Priepke H, Ries U, Stassen JM, et al. (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45: 1757-1766.
40. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high-virulence community acquired MRSA. Lancet 359: 1819-1827.
41. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, et al. (2001) Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357: 1225-1240.
42. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG, (2010) The pathogenesis of sepsis. Annu Rev Pathol Mech Dis 6: 19-48.
43. Warren HS, Suffredini AF, Eichacker PQ, Munford RS, (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027-1030.
44. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, et al. (2009) Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 37: 1185-1196.
45. Di Nisio M, Middeldorp S, Buller HR, (2005) Direct thrombin inhibitors. N Engl J Med 353: 1028-1040.
46. Marlar RA, Kleiss AJ, Griffin JH, (1981) Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann NY Acad Sci 370: 303-310.
47. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
48. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, et al. (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36: 222-231.
49. Taylor FBJ, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, et al. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925.
50. Martin GS, Mannino DM, Eaton S, Moss M, (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
51. Liu C, Bayer AS, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52: 285-292.
52. Walsh CT, (1993) Vancomycin resistance: decoding the molecular logic. Science 261: 308-309.
53. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, et al. (2006) Daptomycin versus standard therapy for bacteremia and edocarditis caused by Staphylococcus aureus. N Engl J Med 355: 653-665.
54. Klevens RM, Edwards JR, Gaynes RP, System NNIS, (2008) The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 47: 927-930.
55. McCarthy AJ, Lindsay JA, (2010) Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiology 10: 173.
56. Coleman DC, Sullivan DJ, Russell RJ, Arbuthnott JP, Carey BF, et al. (1989) Staphylococcus aureus bacteriophages mediating the simultaneous lysogenic conversion of beta-lysin, staphylokinase and enterotoxin A: a molecular mechanism of triple conversion. J Gen Microbiol 135: 1679-1697.
57. Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, et al. (1991) On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 266: 11826-11832.
58. Mölkänen T, Tyynelä J, Helin J, Kalkkinen N, Kuusela P, (2002) Enhanced activation of bound plasminogen on Staphylococcus aureus by staphylokinase. FEBS Lett 517: 72-78.
59. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, et al. (2004) Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 172: 1169-1176.
60. Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O, (2000) Staphylococcus aureus mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc Natl Acad Sci U S A 97: 5510-5515.
61. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K, (2007) Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes. J Bacteriol 190: 300-310.
62. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, et al. (2006) Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367: 731-739.
63. Donahue JP, Patel H, Anderson WF, Hawiger J, (1994) Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen gamma chain obtained by carrier protein-driven characterization. Proc Natl Acad Sci U S A 91: 12178-12182.
64. Ware S, Donahue JP, Hawiger J, Anderson WF, (1999) Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein Sci 8: 2663-2671.
65. Wolberg AS, (2007) Thrombin generation and fibrin structure. Blood Rev 21: 131-142.
66. Schneewind O, Mihaylova-Petkov D, Model P, (1993) Cell wall sorting signals in surface protein of Gram-positive bacteria. EMBO 12: 4803-4811.
67. DeDent AC, Missiakas DM, Schneewind O, (2008) Signal peptides direct surface proteins to two distinct envelope locations of Staphylococcus aureus. EMBO J 27: 2656-2668.